The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
OBJECTIVE: To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or very-late antigen-4) on MRI lesion activity in MS. METHODS: A randomized, double-blind, placebo-controlled trial in 72 patients with active relapsing-remitting and secon...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1999
|
| _version_ | 1797053266084757504 |
|---|---|
| author | Tubridy, N Behan, P Capildeo, R Chaudhuri, A Forbes, R Hawkins, C Hughes, R Palace, J Sharrack, B Swingler, R Young, C Moseley, I MacManus, D Donoghue, S Miller, D |
| author_facet | Tubridy, N Behan, P Capildeo, R Chaudhuri, A Forbes, R Hawkins, C Hughes, R Palace, J Sharrack, B Swingler, R Young, C Moseley, I MacManus, D Donoghue, S Miller, D |
| author_sort | Tubridy, N |
| collection | OXFORD |
| description | OBJECTIVE: To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or very-late antigen-4) on MRI lesion activity in MS. METHODS: A randomized, double-blind, placebo-controlled trial in 72 patients with active relapsing-remitting and secondary progressive MS was performed. Each patient received two IV infusions of anti-alpha4 integrin antibody (natalizumab; Antegren) or placebo 4 weeks apart and was followed up for 24 weeks with serial MRI and clinical assessment. RESULTS: The treated group exhibited significantly fewer new active lesions (mean 1.8 versus 3.6 per patient) and new enhancing lesions (mean 1.6 versus 3.3 per patient) than the placebo group over the first 12 weeks. There was no significant difference in the number of new active or new enhancing lesions in the second 12 weeks of the study. The number of baseline-enhancing lesions (i.e., lesions that enhanced on the baseline scan) that continued to enhance 4 weeks following the first treatment was not significantly different between the two groups. The number of patients with acute MS exacerbations was not significantly different in the two groups during the first 12 weeks (9 in the treated group versus 10 in placebo) but was higher in the treatment group in the second 12 weeks (14 versus 3; p = 0.005). The study was not, however, designed to look definitively at the effect of treatment on relapse rate. Treatment was well tolerated. CONCLUSIONS: Short-term treatment with monoclonal antibody against alpha4 integrin results in a significant reduction in the number of new active lesions on MRI. Further studies will be required to determine the longer term effect of this treatment on MRI and clinical outcomes. |
| first_indexed | 2024-03-06T18:41:28Z |
| format | Journal article |
| id | oxford-uuid:0d01e46c-0c63-437a-8ac2-2a5d4db1a21f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:41:28Z |
| publishDate | 1999 |
| record_format | dspace |
| spelling | oxford-uuid:0d01e46c-0c63-437a-8ac2-2a5d4db1a21f2022-03-26T09:38:16ZThe effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0d01e46c-0c63-437a-8ac2-2a5d4db1a21fEnglishSymplectic Elements at Oxford1999Tubridy, NBehan, PCapildeo, RChaudhuri, AForbes, RHawkins, CHughes, RPalace, JSharrack, BSwingler, RYoung, CMoseley, IMacManus, DDonoghue, SMiller, DOBJECTIVE: To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or very-late antigen-4) on MRI lesion activity in MS. METHODS: A randomized, double-blind, placebo-controlled trial in 72 patients with active relapsing-remitting and secondary progressive MS was performed. Each patient received two IV infusions of anti-alpha4 integrin antibody (natalizumab; Antegren) or placebo 4 weeks apart and was followed up for 24 weeks with serial MRI and clinical assessment. RESULTS: The treated group exhibited significantly fewer new active lesions (mean 1.8 versus 3.6 per patient) and new enhancing lesions (mean 1.6 versus 3.3 per patient) than the placebo group over the first 12 weeks. There was no significant difference in the number of new active or new enhancing lesions in the second 12 weeks of the study. The number of baseline-enhancing lesions (i.e., lesions that enhanced on the baseline scan) that continued to enhance 4 weeks following the first treatment was not significantly different between the two groups. The number of patients with acute MS exacerbations was not significantly different in the two groups during the first 12 weeks (9 in the treated group versus 10 in placebo) but was higher in the treatment group in the second 12 weeks (14 versus 3; p = 0.005). The study was not, however, designed to look definitively at the effect of treatment on relapse rate. Treatment was well tolerated. CONCLUSIONS: Short-term treatment with monoclonal antibody against alpha4 integrin results in a significant reduction in the number of new active lesions on MRI. Further studies will be required to determine the longer term effect of this treatment on MRI and clinical outcomes. |
| spellingShingle | Tubridy, N Behan, P Capildeo, R Chaudhuri, A Forbes, R Hawkins, C Hughes, R Palace, J Sharrack, B Swingler, R Young, C Moseley, I MacManus, D Donoghue, S Miller, D The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. |
| title | The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. |
| title_full | The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. |
| title_fullStr | The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. |
| title_full_unstemmed | The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. |
| title_short | The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. |
| title_sort | effect of anti alpha4 integrin antibody on brain lesion activity in ms the uk antegren study group |
| work_keys_str_mv | AT tubridyn theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT behanp theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT capildeor theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT chaudhuria theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT forbesr theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT hawkinsc theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT hughesr theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT palacej theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT sharrackb theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT swinglerr theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT youngc theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT moseleyi theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT macmanusd theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT donoghues theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT millerd theeffectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT tubridyn effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT behanp effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT capildeor effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT chaudhuria effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT forbesr effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT hawkinsc effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT hughesr effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT palacej effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT sharrackb effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT swinglerr effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT youngc effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT moseleyi effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT macmanusd effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT donoghues effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup AT millerd effectofantialpha4integrinantibodyonbrainlesionactivityinmstheukantegrenstudygroup |